| Outcome |
Non-AT/AU (n=1105) |
Matched Controls Without AA (n=3315) |
P Value |
AT/AU (n=130) |
Matched Controls Without AA (n=390) |
P Value |
| HCRU visits, mean ± SD |
|
|
|
|
|
|
| Outpatient visits |
11.6±11.6 |
8.0±12.8 |
<.001 |
14.5±11.8 |
7.1±9.6 |
<.001 |
| Dermatologist visits |
3.4±5.1 |
0.4±1.7 |
<.001 |
3.6±4.3 |
0.3±1.0 |
<.001 |
| Psychiatrist visits |
0.3±2.3 |
0.3±1.6 |
.559 |
0.1±0.7 |
0.3±1.3 |
.272 |
| Psychologist visits |
0.3±1.8 |
0.4±3.7 |
.278 |
0.2±1.6 |
0.1±0.7 |
.199 |
| Any dermatologist visit, n (%) |
903 (81.7) |
548 (16.5) |
<.001 |
93 (71.5) |
56 (14.4) |
<.001 |
| Any psychiatrist visit, n (%) |
55 (5.0) |
195 (5.9) |
.293 |
7 (5.4) |
22 (5.6) |
1.000 |
| Any psychologist visit, n (%) |
45 (4.1) |
140 (4.2) |
.896 |
6 (4.6) |
14 (3.6) |
.792 |
| Medication use, n (%) |
|
|
|
|
|
|
| Corticosteroids |
|
|
|
|
|
|
| Topical |
402 (36.4) |
51 (1.5) |
<.001 |
38 (29.2) |
1 (0.3) |
<.001 |
| Injectable |
568 (51.4) |
30 (0.9) |
<.001 |
38 (29.2) |
6 (1.5) |
<.001 |
| Oral |
121 (11.0) |
234 (7.1) |
<.001 |
37 (28.5) |
20 (5.1) |
<.001 |
| Methotrexate |
14 (1.3) |
1 (0.1) |
<.001 |
11 (8.5) |
1 (0.3) |
<.001 |
| Mental health |
| Antidepressants |
82 (7.4) |
312 (9.4) |
.051 |
16 (12.3) |
27 (6.9) |
.081 |
| Anxiolytics |
48 (4.3) |
129 (3.9) |
.565 |
5 (3.8) |
12 (3.1) |
.887 |